|
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 Years of Age |
|
Investigator: T Barrett [email protected] Sponsor: Astra Zeneca |
|
Summary: The purpose of this research study is to evaluate the effectiveness and safety of dapagliflozin and saxagliptin in patients with Type 2 Diabetes who are aged 10 to below 18 years old and are currently taking metformin, insulin, or both medicines. |
|
Start Date: |
|
End Date: |
|
Further Information: |
|
DINAMO: A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescents With Type 2 Diabetes Mellitus |
|
Investigator: Christina Wei, [email protected] Sponsor: Boehringer Ingelheim |
|
Summary: The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking metformin, insulin or both drugs. |
|
Start Date: 20/03/2018 |
|
End Date: 31/01/2022 |
|
Further Information: https://clinicaltrials.gov/ct2/show/NCT03429543?term=DINAMO&rank=2 |